2025年,中国生物制药(1177.HK)旗下正大天晴、北京泰德制药、礼新医药、南京正大天晴等成员企业共有18款1类创新药首次获得国家药品监督管理局(NMPA)临床试验批准,涵盖肿瘤、代谢、外科/镇痛、呼吸等多个治疗领域,包括ADC(抗体偶联药物)、PROTAC(蛋白降解靶向嵌合体)、双特异性抗体、小分子抑制剂等创新产品。其中,多款产品在美国、澳洲同步开发,充分体现了中国生物制药以创新驱动发展的...
Source Link2025年,中国生物制药(1177.HK)旗下正大天晴、北京泰德制药、礼新医药、南京正大天晴等成员企业共有18款1类创新药首次获得国家药品监督管理局(NMPA)临床试验批准,涵盖肿瘤、代谢、外科/镇痛、呼吸等多个治疗领域,包括ADC(抗体偶联药物)、PROTAC(蛋白降解靶向嵌合体)、双特异性抗体、小分子抑制剂等创新产品。其中,多款产品在美国、澳洲同步开发,充分体现了中国生物制药以创新驱动发展的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.